Company Overview
| Stock Name | Cstone Pharma-B |
|---|---|
| Stock Code | 02616 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們為一間臨床階段生物製藥公司,專注於開發及商業化創新腫瘤免疫及分子靶向藥物,以滿足癌症治療的殷切醫療需求。 |
| Listing Date | 2019-02-26 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國 上海市 浦東新區 張衡路1000號 25號樓 郵編:201203 |
| Business Address (Hong Kong) | 香港 灣仔 皇后大道東248號 陽光中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | cstonepharma.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 12.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 500 shares |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2019-02-14 to 2019-02-19 |
| Global Offering Shares | 186,396,000 shares |
| HK Public Offer Shares (Initial) | 18,640,000 shares (10.0%) |
| Public Offer Lots (Initial) | 37,280lots (Pool A18,640lots,Pool B18,640lots) |
| International Placing Shares (Initial) | 167,756,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 984,051,532 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 33.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 2,236,752,000 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 9.65B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 亏损约人民币344.0百万元 |
| Period-End Cash Balance | 人民币83.4百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | 約412百萬美元 |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 |
|---|---|---|
| Other income and gains, net | 187 | 9,185 |
| Administrative expenses | -15,050 | -39,335 |
| Net finance costs | -240 | -60 |
| Profit for the year | -253,039 | -342,547 |
| Profit attributable to owners | -246,091 | -308,904 |
Balance Sheet
| Item | 2016 | 2017 |
|---|---|---|
| Cash and cash equivalents | 59,539 | 83,390 |
| Total current assets | 824,816 | 545,260 |
| Total assets | 826,139 | 564,280 |
| Total current liabilities | 59,184 | 113,228 |
| Total liabilities | 59,184 | 113,228 |
| Total equity | 766,955 | 451,052 |
| Equity attributable to owners | 712,688 | 426,338 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018-09 |
|---|---|---|---|
| Net cash from operating activities | -213,006 | -240,186 | |
| Net cash from investing activities | -753,469 | 268,300 | |
| Net cash from financing activities | 1,010,503 | -300 | |
| Net increase in cash | 44,028 | 27,814 | |
| Depreciation of PP&E | 67 | 811 | 3,742 |
| Amortisation of intangible assets | 2 | 10 | 111 |
| Purchase of PP&E | -1,101 | -12,130 | -4,432 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 12.86 |
|---|---|
| First Day Open | HK$ 13.32 |
| First Day Change | 7.17% |
| First Day Volume | 57486000.0 |
| First Day Turnover | 784345000.0 |
| Use of Proceeds | 1、預計約622.17百萬港元(相當于所得款項凈額的30.0%)將分配至以下我們 的核心候選產品;
2、預計約829.56百萬港元(相當于所得款項凈額的40.0%)將分配至以下管線 中其余八種臨床及IND階段候選藥物;
3、預計約414.78百萬港元(相當于所得款項凈額的20%)將用于為研發管線中 其余五種候選藥物以及研發和尋求新候選藥物的許可提供資金;
4、預計約207.39百萬港元(相當于所得款項凈額的10%)將用作營運資金及其 他一般公司用途。 |
Underwriting Syndicate
Overall Coordinators (4)
Joint Bookrunners (4)
Joint Lead Managers (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Boyu Capital Opportunities Master Fund | 156,936,000 HKD | — | 7.02% | — | 6 months | 2019-08-26 |
| 2 | GIC Private Limited | 313,872,000 HKD | — | 14.03% | — | 6 months | 2019-08-26 |
| 3 | Indus Capital Partners,LLC | 117,702,000 HKD | — | 5.26% | — | 6 months | 2019-08-26 |
| 4 | Ishana Capital Limited | 156,936,000 HKD | — | 7.02% | — | 6 months | 2019-08-26 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 江寧軍 | — |
| Company Secretary | 楊靜文 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | WuXi Healthcare Ventures持有29.76%;Graceful Beauty Limited持有14.93%;正則原石持有9.98%。 |
|---|




